Connect with Veranex delegates:
Joe Ferrara, Chief Strategy Officer
Patricia Deverka, SVP, Commercial Strategy and Market Access
Amit Jain, Vice President, Commercial Strategy and Market Access
August 22, 2022 1:35 p.m. ET
Early Detection, Earlier Intervention, and Higher Impact: Access and Value in an Evolving Precision Medicine Landscape
As our understanding of the basis of disease grows through advanced diagnostics, big data, and analytics, delivering the right treatment to the right patient at the right time depends not only on the science, but also on insights regarding how this information fits into a complex healthcare delivery system. From in vitro diagnostics to imaging and digital tools, activating precision medicine also means delivering the right insights to the right stakeholders at the right time. Broad and timely access to innovative diagnostic technologies and informatics tools that inform clinical decision making requires a deep understanding of both the patient journey and payer evidence expectations for coverage decision making.
In parallel, as the number of approved targeting and immunotherapies grows with increasing focus on treatment at earlier stages of disease, it becomes critical to understand CDx and non-CDx testing landscapes alike. The convergence of technologies required to provide actionable insights to clinicians and patients requires innovators to take a holistic view of how payers and other stakeholders assess the value of testing across the oncology clinical pathway. Accordingly, this presentation will focus on the continuum of oncology patient assessment tools, from early detection through testing for minimal residual disease. The discussion will highlight evolving payer and clinician value perspectives as reflected in payer coverage, payment landscape, and implications for innovators.
Chief Strategy Officer
SVP, Commercial Strategy & Market Access